**Section: Contact Information**

First Name: Tabitha  
Last Name: Cooney  
Institution: Dana Farber Cancer Institute  
Address 1: 450 Brookline Avenue  
City: Boston  
State/Province/Region: MA  
Country: United States  
Zip/Postal Code: 02215-5450  
Phone Number: 6176324309  
Alternate Phone Number:  
Email Address: tabitha_cooney@dfci.harvard.edu

**Section: Project Requirements and Description**

**Group: Requirements to submit AOI**

A comprehensive review of previously published data has been completed. : Yes  
The specific aims are clear and focused. : Yes  
The investigator has appropriate experience and expertise to develop the concept proposal; if not, has identified a mentor or senior co-investigator. : Yes  
The investigator agrees to develop an initial draft of the concept proposal within 6 weeks of approval of the AOI and to finalize the concept proposal within 6 months. : Yes  
Project Title: Meningiomas in Survivors of Childhood Cancer

Planned research population (eligibility criteria):  
The study population will consist of all childhood cancer survivors enrolled in both the original and expanded CCSS cohorts. Individuals with unknown treatment exposure will be excluded. Cases of subsequent meningioma will be identified.  
Proposed specific aims:  
1) To describe the cumulative incidence of meningiomas in survivors of childhood cancer across the original and expanded cohorts. Hypotheses: The incidence of meningioma increases with time from treatment exposure and does not plateau. By treatment era/decade, the incidence of meningioma has decreased due to reduced use of cranial radiation.  
2) To describe the patterns of multiple meningiomas among childhood cancer survivors. Hypothesis: More than prior estimates of 10-14% of survivors with meningioma will develop multiple meningioma. Of those with multiple, a portion will be recurrent meningioma.  
3) To identify treatment, disease, and sociodemographic characteristics that predict the risk of meningioma. Hypothesis: Increasing cranial radiation dose, younger age at diagnosis, and female gender will be identified as independent risk factors for meningioma. Intrathecal methotrexate will not be identified.  
4) To construct the radiation dose response relationship using first pass radiation exposure data. Hypothesis: A statistically significant radiation dose-response
relationship will be observed for meningioma consistent with prior CCSS reports and reports from other similar cohort studies.

5) To determine all-cause and meningioma-specific mortality among childhood cancer survivors with subsequent meningioma. Hypothesis: Three- and five-year overall survival will be consistent with prior CCSS report, and cause of death will vary and include meningioma, progression of primary cancer, and secondary cancer.

Will the project require non-CCSS funding to complete? : No
If yes, what would be the anticipated source(s) and timeline(s) for securing funding? :

**Group: Does this project require contact of CCSS study subjects for:**
Additional self-reported information : No
Biological samples : No
Medical record data : No
If yes to any of the above, please briefly describe. :

**Group: What CCSS Working Group(s) would likely be involved? (Check all that apply)**
Second Malignancy : Primary
Chronic Disease :
Psychology / Neuropsychology :
Genetics :
Cancer Control : Secondary
Epidemiology / Biostatistics :

**Section: Outcomes or Correlative Factors**
Late mortality : Secondary
Second Malignancy : Primary

**Group: Health Behaviors**
Tobacco :
Alcohol :
Physical activity :
Medical screening :
Other :
If other, please specify :

**Group: Psychosocial**
Insurance :
Marriage :
Education :
Employment :
Other :
If other, please specify :

**Group: Medical Conditions**
Hearing/Vision/Speech :
Hormonal systems :
Heart and vascular :
Respiratory:

Digestive:

Surgical procedures:

Brain and nervous system:

Other:

If other, please specify:

**Group: Medications**

Describe medications:

**Group: Psychologic/Quality of Life**

BSI-18:

SF-36:

CCSS-NCQ:

PTS:

PTG:

Other:

If other, please specify:

**Group: Other**

Pregnancy and offspring:

Family history:

Chronic conditions (CTCAE v3):

Health status:

**Group: Demographic**

Age: Correlative Factors

Race: Correlative Factors

Sex: Correlative Factors

Other:

If other, please specify:

**Group: Cancer treatment**

Chemotherapy: Correlative Factors

Radiation therapy: Correlative Factors

Surgery: Correlative Factors

**Section: Anticipated Sources of Statistical Support**

CCSS Statistical Center: Yes

Local institutional statistician:

If local, please provide the name(s) and contact information of the statistician(s) to be involved.

Will this project utilize CCSS biologic samples?: No

If yes, which of the following?:

If other, please explain:

**Section: Other General Comments**

Other General Comments:

I agree to share this information with St. Jude: Yes